Cytokine antagonists for the treatment of sensorineural hearing loss

Abstract

Specific Cytokine Antagonists, including TNF antagonists and / or Interleukin-1 antagonists, are used as novel therapeutic agents for the treatment of hearing loss, including presbycusis and other forms of sensorineural hearing loss. The present invention provides a method for inhibiting the action of TNF and / or IL-1 antagonists for treating hearing loss in a human by administering a TNF antagonist and / or an IL-1 antagonist for reducing the inflammation affecting the auditory apparatus of said human, or for modulating the immune response affecting the auditory apparatus of said human, by administering a therapeutically effective dosage level to said human of a TNF antagonist and / or an IL-1 antagonist. Administration may be systemic, through the subcutaneous, intramuscular, oral, or intravenous routes; or by delivering an anatomically localized application in the region of the head. The TNF antagonist is selected from the group consisting of etanercept, infliximab, D2E7, CDP 571, or thalidomide; and the IL-1 antagonist is either IL-1 RA or IL-1R type II receptor. Antiviral agents may be added for treating certain patients.

Description

[0001] This is a continuation-in-part of application Ser. No. 09 / 654,996, filed on Sep. 5, 2000, which is a continuation-in-part of application Ser. No. 09 / 563,651, filed on May 2, 2000, which is a continuation-in-part of application Ser. No. 09 / 476,643, filed on Dec. 31, 1999, which is a continuation-in-part of application Ser. No. 09 / 275,070, filed on Mar. 23, 1999, now U.S. Pat. No. 6,015,557, which is a continuation-in-part of application Ser. No. 09 / 256,388, filed on Feb. 24, 1999, now abandoned.[0002] The present invention is directed to specific cytokine antagonists, including TNF antagonists and IL-1 antagonists, for the treatment of hearing loss, including sensorineural hearing loss and presbycusis. The invention also includes methods of administration for these antagonists.[0003] Hearing loss occurs in humans in many forms. Hearing is essential to the normal conduct of one's daily activities and people with impaired hearing have many difficulties. Hearing loss can date fro...

AI Technical Summary

Benefits of technology

[0029] Another object of the present invention to provide a TNF antagonist for the treatment of presbycusis in a human such that the use of this antagonist results in improved hearing.

[0030] Another object of the present invention to provide a TNF antagonist for the treatment of sensorineural hearing loss in a human such that the use of this antagonist results in improved hearing.

[0031] Another object of the present invention to provide a TNF antagonist for the treatment of sensorineural hearing loss in a human such that the use of this antagonist results in improved hearing without the use of a hearing aid, in a manner that is both safe and effective.

Problems solved by technology

Presbycusis, or age-related hearing loss, affects one-third of the U.S. population over age 75, and presents a significant hardship to these people, many of whom are faced with the burden of other age-related illnesses.

At this time, it is difficult to determine the degree to which any individual patient will respond to treatment with the cytokine antagonists discussed herein.

The use of these medications in this manner has been demonstrated to be synergistic when used to treat an arthritis model in animals.

Sensorineural hearing loss is an important cause of disability in children.

Many of the causes are genetic, and these can lead to profound deafness.